Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab (MITO16/MANGO-2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01706120 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 15, 2012
Last Update Posted : March 24, 2023
|
Sponsor:
National Cancer Institute, Naples
Collaborator:
Mario Negri Institute for Pharmacological Research
Information provided by (Responsible Party):
National Cancer Institute, Naples
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The addition of bevacizumab to first-line chemotherapy has been shown to improve progression free survival for patients with ovarian cancer. The purpose of this study is to explore the potential role of clinical and biologic factors in identifying those patients who benefit most from this combined therapy in terms of progression free and overall survival.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ovarian Cancer | Drug: Bevacizumab Drug: Paclitaxel Drug: Carboplatin | Phase 4 |
MITO-16 - MANGO-OV2 is a single-arm, open-label, non-comparative, multicenter, phase IV study. Patients will receive a combination of bevacizumab, paclitaxel and carboplatin as first line treatment (in-label dose and scheduling). This is an exploratory study attempting to identify potential prognostic clinical factors(such as hypertension) and prognostic biologic factors. Overall, 2 types of biomarkers are considered. Dynamic biomarkers are those expressing the changing nature of the disease in relation to the treatment or simply the tumour progression, these are typically not inherited. Genetic biomarkers are typically inherited and are expression of some characteristics potentially able to interfere with the treatment effect (i.e. Pharmacogenomics).
The safety of this regimen in routine clinical practice will also be described.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 400 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS |
| Study Start Date : | October 2012 |
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | December 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Ovarian cancer
MedlinePlus related topics:
Ovarian Cancer
| Arm | Intervention/treatment |
|---|---|
First-line chemotherapy with bevacizumab
|
Drug: Bevacizumab
• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
Other Name: Avastin Drug: Paclitaxel • Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles Drug: Carboplatin • Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles |
Primary Outcome Measures :
- expression of soluble and tissutal biomarkers [ Time Frame: measured at baseline, at completion of chemotherapy, at disease progression or bevacizumab completion up to 15 monthsfor each patient ]
Secondary Outcome Measures :
- progression free survival [ Time Frame: one year ]
- overall survival [ Time Frame: three years ]
- worst grade toxicity per patient [ Time Frame: evaluated every 3 weeks up to 15 month ]according to Common Toxicity Criteria for Adverse Events v. 4.03
- number of patients taking oral antidiabetic therapy [ Time Frame: at baseline ]
- number of patients taking antithrombotic therapy [ Time Frame: at baseline ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Female patients ≥18 years of age.
- Patients with histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma, including mixed Mullerian Tumours Or Recurrent early stage epithelial ovarian or fallopian tube carcinoma treated with surgery alone.
- FIGO stage IIIB & C or IV
- ECOG Performance Status of 0-2.
- Life expectancy of at least 12 weeks.
- Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements.
- Availability of tumour samples for molecular analyses
Exclusion Criteria:
Cancer related
- Ovarian tumours with low malignant potential (i.e. borderline tumours)
- Previous systemic anti-cancer therapy for advanced ovarian cancer.
- History or evidence of brain metastases or spinal cord compression.
-
History or evidence of synchronous primary endometrial carcinoma, unless all of the following criteria related to the endometrial carcinoma are met:
- stage ≤Ia
- no more than superficial myometrial invasion
- no lymphovascular invasion
- not poorly differentiated (grade 3 or papillary serous or clear cell carcinoma).
- Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
Other-treatment related
- Any prior radiotherapy to the pelvis or abdomen.
- Surgery (including open biopsy) within 4 weeks prior to the first bevacizumab dose or planned (In this case the patient can be enrolled but the administration of bevacizumab should be omitted at first cycle).
- Current or recent (within 10 days prior to the first study drug dose) use of full-dose oral or parenteral anticoagulant or thrombolytic agent for therapeutic purposes (except for central venous access patency, in which case international normalized ratio [INR] must be maintained below 1.5). Post operative prophylaxis with low molecular weight heparin sc is allowed.
- Current or recent (within 30 days of first study dosing) treatment with another investigational drug.
Laboratory related
- Inadequate bone marrow function: ANC: <1.5 x 109/l, or platelet count <100 x 109/l or Haemoglobin <9 g/dl. Patients may be transfused to maintain haemoglobin values ≥9 g/dl.
-
Inadequate coagulation parameters:
- activated partial thromboplastin time (APTT) >1.5 xULN or
- INR >1.5
-
Inadequate liver function, defined as:
- serum (total) bilirubin >1.5 x the upper limit of normal (ULN) for the institution
- AST/SGOT or ALT/SGPT >2.5 x ULN.
- Inadequate renal function, defined as serum creatinine >2.0 mg/dl or >177 micromol/l
- Proteinuria >1g in a 24-hour urine collection (to be performed only among patients who showed a ≥3+ at urine dipstick).
Patient related
- Pregnant or lactating patients.
- History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA) or sub-arachnoid haemorrhage within ≤6 months prior to the first study treatment).
-
Uncontrolled hypertension (sustained systolic >150 mm Hg and/or diastolic >100 mm Hg despite antihypertensive therapy) or clinically significant (i.e. active) cardiovascular disease, including:
- myocardial infarction or unstable angina within ≤6 months prior to the first study treatment
- New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF)
- serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia)
- peripheral vascular disease ≥grade 3 (i.e. symptomatic and interfering with activities of daily living requiring repair or revision).
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the first study treatment.
- Non-healing wound, ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require three weekly wound examinations.
- Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01706120
Locations
Show 47 study locations
Sponsors and Collaborators
National Cancer Institute, Naples
Mario Negri Institute for Pharmacological Research
Investigators
| Principal Investigator: | Sandro Pignata, M.D., Ph.D. | National Cancer Institute, Naples | |
| Principal Investigator: | Nicoletta Colombo, M.D. | European Institute of Oncology | |
| Principal Investigator: | Francesco Perrone, M.D., Ph.D. | National Cancer Institute, Naples | |
| Principal Investigator: | Gennaro Daniele, M.D., Ph.D. | National Cancer Institute, Naples | |
| Principal Investigator: | Roldano Fossati, M.D. | Mario Negri Institute | |
| Principal Investigator: | Ciro Gallo, M.D. | University of Campania "Luigi Vanvitelli" | |
| Principal Investigator: | Irene Floriani, Ph.D. | Mario Negri Institute |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | National Cancer Institute, Naples |
| ClinicalTrials.gov Identifier: | NCT01706120 |
| Other Study ID Numbers: |
MITO-16 - MANGO-OV2 2012-003043-29 ( EudraCT Number ) |
| First Posted: | October 15, 2012 Key Record Dates |
| Last Update Posted: | March 24, 2023 |
| Last Verified: | March 2023 |
Keywords provided by National Cancer Institute, Naples:
|
prognostic factors biologic factors clinical factors routine clinical practice |
Additional relevant MeSH terms:
|
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Genital Neoplasms, Female Urogenital Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Adnexal Diseases Endocrine System Diseases Gonadal Disorders Carcinoma Paclitaxel |
Bevacizumab Carboplatin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |